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Abstract
STAT5A (signal transducer and activator of transcription 5A) is a transcription factor 
that plays a role in adipocyte development and function. In this study, we report DBC1 
(deleted in breast cancer 1 – also known as CCAR2) as a novel STAT5A-interacting protein. 
DBC1 has been primarily studied in tumor cells, but there is evidence that loss of this 
protein may promote metabolic health in mice. Currently, the functions of DBC1 in 
mature adipocytes are largely unknown. Using immunoprecipitation and immunoblotting 
techniques, we confirmed that there is an association between endogenous STAT5A 
and DBC1 proteins under physiological conditions in the adipocyte nucleus that is not 
dependent upon STAT5A tyrosine phosphorylation. We used siRNA to knockdown 
DBC1 in 3T3-L1 adipocytes to determine the impact on STAT5A activity, adipocyte gene 
expression and TNFα (tumor necrosis factor α)-regulated lipolysis. The loss of DBC1 did 
not affect the expression of several STAT5A target genes including Socs3, Cish, Bcl6, 
Socs2 and Igf1. However, we did observe decreased levels of TNFα-induced glycerol and 
free fatty acids released from adipocytes with reduced DBC1 expression. In addition, 
DBC1-knockdown adipocytes had increased Glut4 expression. In summary, DBC1 can 
associate with STAT5A in adipocyte nucleus, but it does not appear to impact regulation 
of STAT5A target genes. Loss of adipocyte DBC1 modestly increases Glut4 gene expression 
and reduces TNFα-induced lipolysis. These observations are consistent with in vivo 
observations that show loss of DBC1 promotes metabolic health in mice.
Introduction
Signal transducer and activator of transcription 5A 
(STAT5A) is a transcription factor that utilizes the janus 
kinase/signal transducer and activator of transcription 
(JAK/STAT) pathway to mediate the biological actions 
of a variety of hormones and cytokines. In vivo and in 
vitro approaches have demonstrated that STAT5A has 
a prominent role in adipogenesis (Teglund et  al. 1998, 
Floyd & Stephens 2003, Stewart et  al. 2011, Wakao 
et al. 2011, Tse et al. 2013). Growth hormone (GH) is a 
primary activator of STAT5A in adipocytes. Upon GH 
activation, STAT5A can activate or repress several genes 
including suppressor of cytokine signaling 3 (Socs3), 
cytokine-inducible SH2-containing protein (Cish), B-cell 
lymphoma 6 (Bcl6), fatty acid synthase (Fasn), adiponectin 
and pyruvate dehydrogenase kinase 4 (Pdk4) in adipocytes 
(Hogan & Stephens 2005, Story & Stephens 2006, White 
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et al. 2007, 2016, Lin et al. 2014). Despite the identification 
of these direct STAT5 target genes, very little is known 
about the molecular mechanisms that contribute to 
the ability of STAT5A to regulate gene expression in 
adipocytes. To further investigate the functions of 
STAT5A in adipocytes, we sought to identify novel 
proteins that interact with STAT5A by performing a non-
biased co-immunoprecipitation and mass spectrometry 
approach (Richard et al. 2017). This approach identified 
DBC1 (deleted in breast cancer 1) as a potential STAT5A-
interacting protein.
DBC1, also referred to as CCAR2 (cell cycle and 
apoptosis regulator 2), is a pleiotropic protein that is 
primarily localized in the nucleus. DBC1 has been shown 
to physically interact and negatively regulate several 
epigenetic modifiers including sirtuin 1 (SIRT1), histone 
deacetylase 3 (HDAC3) and suppressor of variegation 3–9 
homolog 1 (SUV39H1) (Zhao et  al. 2008, Li et  al. 2009, 
Chini et al. 2010). SIRT1 is a NAD-dependent deacetylase 
involved in a variety of cellular processes including 
regulation of obesity-associated metabolic diseases, cancer, 
aging and cellular senescence (Rahman & Islam 2011). A 
loss of DBC1 expression is associated with increased SIRT1 
activity in A459 human alveolar basal epithelial cells (Zhao 
et al. 2008). DBC1 also interacts and negatively regulates 
estrogen receptor β (ERβ) and breast cancer 1 susceptibility 
protein 1 (BRCA1) (Hiraike et al. 2010, Koyama et al. 2010). 
In addition, DBC1 can be present in a complex with and 
positively regulate estrogen receptor α (ERα), androgen 
receptor (AR) and nuclear receptor subfamily 1, group D, 
member 2 (Rev-erbα) (Fu et al. 2009, Yu et al. 2011, Chini 
et  al. 2013). DBC1 has also been shown to physically 
interact with and positively regulate IKK-α and IKK-β; two 
kinases that are part of the inhibitor of kappa B Kinase 
(IKK) complex that affects nuclear factor kappa B (NF-κB) 
signaling and transcriptional activity (Kong et al. 2015).
To date, most DBC1 studies have been performed 
in tumor cells and little is known about the function of 
DBC1 in adipocytes. However, studies have shown that 
knockdown of DBC1 in 3T3-L1 preadipocytes promotes 
adipocyte development in vitro (Moreno-Navarrete et  al. 
2015a). Also, DBC1-knockout mice have increased fat 
accumulation in adipose tissue, but remain metabolically 
healthy (Escande et  al. 2015). DBC1-knockout mice 
maintained insulin sensitivity, had lower circulating free 
fatty acids and were protected against atherosclerosis and 
liver steatosis following diet-induced obesity (Escande 
et al. 2015). Other studies have shown that loss of DBC1 
in 3T3-L1 adipocytes results in decreased expression 
of inflammatory markers such as interleukin 6 (IL-6), 
monocyte chemoattractant protein 1 (MCP1) and tumor 
necrosis factor-alpha (TNFα), indicating that DBC1 may 
influence adipocyte inflammation (Moreno-Navarrete 
et al. 2015b). DBC1 has also been implicated in senescence 
of preadipocytes as loss of DBC1 protects again cellular 
senescence and senescence-driven inflammation in 
obesity (Escande et al. 2014).
Our studies are the first to show that DBC1 is present 
in a complex with STAT5A under physiological conditions 
in the nucleus of adipocytes. However, knockdown 
approaches revealed that DBC1 does not have a profound 
effect on the ability of GH to regulate STAT5 target genes. 
In studies to observe an impact of DBC1 loss in adipocytes, 
we found that DBC1 can impact TNFα-mediated lipolysis 
in mature 3T3-L1 adipocytes. Although DBC1 did not have 
a profound effect on TNFα-mediated changes in Mcp-1 




Murine 3T3-L1 preadipocytes (obtained from Dr Howard 
Green at Harvard University) were grown in Dulbecco’s 
Modified Eagle’s Media (DMEM) (Sigma-Aldrich) with 
10% bovine calf serum. Two days after confluence, 
the preadipocytes were induced to differentiate using 
a standard protocol and 3-isobutyl-methylxanthine, 
dexamethasone, insulin (MDI) induction cocktail plus 
10% fetal bovine serum (FBS) in DMEM (Richard et  al. 
2017). HyClone calf and FBS were purchased from Thermo 
Scientific or GE Healthcare Life Sciences (Marlborough, 
MA). The medium was changed every 48–72 h during 
growth and differentiation. Cells were serum deprived 
by changing the medium to DMEM containing 1% calf 
serum for 16–24 h before treatment with murine GH 
(mGH) or murine TNFα. Recombinant murine GH was 
obtained from Dr. A.F. Parlow at the National Hormone 
and Peptide Program (NHPP; Torrance, CA). Recombinant 
murine TNFα was purchased from Thermo Fisher (Cat #: 
PMC3013).
siRNA-mediated knockdown
3T3-L1 adipocytes (5–7 days post-MDI) were trypsinized 
and re-plated in 6-well, 12-well or 24-well plates at a 
density of 5.8 × 105 cells/cm2 in antibiotic-free medium 
(10% FBS/DMEM). Using the protocol from Dharmacon, 
adipocytes were transfected with 50 nM siRNA 
(Dharmacon, Lafayette, CO, USA; Non-targeting siRNA Cat 
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Table 1 Primer sequences for each gene examined by real-time qPCR.
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#: D-001810-10-50, siRNA targeting DBC1 Cat #: L-047837-
00-0005) and the DharmaFECT Duo reagent (Dharmacon, 
Cat #: T-2010-03) in OptiMEM reduced serum medium 
(Thermo Fisher; Cat #: 31985088). Non-targeting siRNA 
was used as negative control. After 24 h, siRNA-containing 
media was removed, replaced with antibiotic-free 10% 
FBS/DMEM and cells were transfected again with 50 nM 
siRNA. After 24 h, the media was removed and replaced 
with antibiotic-free 10% FBS/DMEM. Cell monolayers 
were collected 72 h following the initial transfection and 
harvested for protein in immunoprecipitation (IP) buffer, 
and for RNA in buffer provided in the RNeasy mini kit 
(Qiagen) to assess knockdown efficiency. Knockdown 
of Cyclophilin B was used as a positive control to assess 
siRNA transfection efficiency in 3T3-L1 adipocytes 
because it is a well-characterized housekeeping gene that 
is not affected by experimental treatments in adipocytes 
and has been validated in our lab. (Dharmacon; Cat #: 
D-001820-02-05).
RNA analysis
Adipocyte monolayers were harvested in lysis buffer 
from the RNeasy mini kit and total RNA was isolated 
from harvested cells using the RNeasy mini kit (Qiagen). 
Ten microliters of purified RNA were used for reverse 
transcription (RT) PCR to generate cDNA according to 
the Applied Biosystems protocol (Applied Biosystems; 
Cat #: 4368813). cDNA was quantitated using the real-
time quantitative PCR (qPCR) method in a total volume 
of 10 µL (2 µL DNA and 8 µL reaction master mix) using 
an Applied Biosystems 7900HT Fast Real-Time PCR 
System and the qPCR amplification program specified in 
the kit (Clontech, Mountain View, CA; Cat #: RR420A). 
Cyclophilin B (Ppib), Ubiquitin B (Ubb) and Nono were 
used as endogenous controls. The following mouse genes 
were examined by RT-qPCR: Ppib, Ubb, Nono, Dbc1 (Ccar2), 
Socs3, Cish, Bcl6, Igf1, Mcp1, Glut4 and adiponectin 
(Adipoq) using primers purchased from Integrated DNA 
Technologies (IDT, Coralville, IA, USA). Primer sequences 
for each gene are shown in Table 1.
Whole-cell extract preparation
Adipocyte monolayers were rinsed once with PBS and 
then harvested in non-denaturing IP buffer as previously 
described (Richard et  al. 2017). The cell extract was 
subjected to a freeze/thaw cycle at −80°C and then passed 
through a 20-gauge needle three times. The whole-cell 
extract was further purified by centrifugation at 13,000 g 
for 10 min at 4°C.
Subcellular fractionation
Mature 3T3-L1 adipocytes were treated with vehicle or 
murine GH prior to subcellular fractionation. Adipocyte 
monolayers from twenty 10 cm culture plates were scraped 
into nuclear homogenization buffer (NHB) (20 mM Tris pH 
7.4, 10 mM NaCl, and 3 mL MgCl2) as previously described 
(Richard et al. 2017). After adding 0.15% IGEPAL CA-630 
(from 10% stock) to the cell suspension, it was homogenized 
on ice using 16 strokes in a Dounce homogenizer. The extract 
was centrifuged at 517 g in a Beckman GS-6KR centrifuge 
with a swinging bucket rotor. Subsequently, the supernatant 
containing cytosol and mitochondria was centrifuged 
as previously described (Richard et  al. 2017). The nuclear 
pellet from the first centrifugation was washed once with 
half of the initial volume of NHB buffer and re-centrifuged 
at 4°C for 5 min at 57 g in the Beckman GS-6KR centrifuge. 
The supernatant was discarded, while the nuclear pellet 
was resuspended in IP buffer and incubated on ice for 1 h. 
To break open the nuclei, the nuclear extract was passed 
through a 20G needle four times and further purified by 
centrifuging at 13,000 g for 10 min at 4°C.
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Measurement of protein concentration
Protein content of cell extracts was quantified using the 
Bicinchoninic acid (BCA) assay kit (Sigma-Aldrich; Cat #: 
BCA1).
Gel electrophoresis and immunoblotting
Samples were separated on 7.5, 10 or 15% SDS-PAGE 
(acrylamide; National Diagnostics, Atlanta, GA, USA; Cat 
#: EC-890) and transferred to nitrocellulose membranes 
(BioRad; Cat #: 162-0115) in 25 mM Tris, 192 mM glycine 
and 20% methanol. After the transfer, the membrane was 
blocked in 4% milk for 1 h at room temperature and then 
immunoblotted. Results were visualized with horseradish 
peroxidase-conjugated secondary antibodies (Jackson 
ImmunoResearch) and enhanced chemiluminescence 
(Pierce/Thermo Scientific).
Immunoprecipitation (IP)
Cell extracts (300–400 µg total protein) were incubated 
with 4–5 µg of immunoprecipitating antibody, diluted 
in IP buffer, overnight on a mini-tube rotator at 4°C. 
Protein A-conjugated agarose beads (IPA300 Protein A 
Resin; Repligen, Waltham, MA, USA; Cat #: 10-2003-02) 
were added to the antibody-epitope mixture, and the 
conjugation reaction proceeded for an additional 3–4 h 
at 4°C with rotation. Following conjugation to the bead 
resin, the beads were pelleted by centrifugation at 16,750 
g for 3 min at 4°C. The supernatant was removed by 
aspiration and the beads were washed three times with 
ice cold 1X IP buffer. Between each wash, the beads were 
pelleted by centrifugation at 13,000 g for 3 min at 4°C 
and the supernatant was removed by aspiration. After 
the final wash, the IP antibody and immunoprecipitated 
proteins were eluted from the bead resin into 2× SDS 
loading buffer by boiling the samples for 10 min at 
100°C. Samples were flicked every 2 min during heat 
step to ensure efficient elution. The samples were briefly 
centrifuged and the supernatants were analyzed by 
SDS-PAGE and immunoblotting. A mock sample 
containing only IP antibody and IP buffer (no cell extract) 
was used as a negative control for each IP experiment.
SIRT1 activity measurement
The deacetylase activity of SIRT1 was measured using a 
fluorometric assay kit (Enzo Life Sciences, Farmingdale, 
NY, USA; Cat #: BML-AK500–0001). Cell extracts (75 µg 
total protein) were incubated with 5 µg of anti-SIRT1 
antibody using the immunoprecipitation method 
described earlier. After the final wash, the samples were 
resuspended in 100 µL of assay buffer provided by the 
assay kit. The manufacturer’s instructions were followed 
and optimized for our samples. Briefly, the deacetylase 
reaction was initiated by adding 50 µM of Fluor de lys 
substrate and 1 mM NAD+ (SIRT1 substrate) to samples. 
After incubating the samples for 20 min at room 
temperature, the reactions were stopped by addition 
of 1X Fluor de lys developer that contained either 1 µM 
trichostatin A (TricA; HDAC inhibitor) or 2 mM of 
nicotinamide (NAM; SIRT1 inhibitor). Samples were 
read in a fluorometer (SpectraMax M5) at an excitation 
wavelength of 360 nm and emission wavelength of 
460 nm.
Measurement of glycerol and free fatty acid release
3T3-L1 adipocytes were transfected with either non-
targeting or DBC1 siRNA as described above. Fifty-four 
hours later, media was changed to 1% calf/DMEM and 
cells were treated with equivalent volume of vehicle 
(0.1% BSA/PBS) or 0.75 nM TNFα overnight. After 
16 h, 1% calf/DMEM was removed and replaced with 
incubation media that consisted of 2% fatty acid free 
bovine serum albumin (BSA; Sigma-Aldrich; Cat #: 
A6003) and 0.1% glucose in glucose-free phenol red-free 
DMEM, and the cells were treated again with vehicle 
(0.1% BSA/PBS) or 0.75 nM TNFα. After 2 h, 500 μL of 
conditioned media was collected and stored at −20°C. 
Glycerol release was measured using 50 μL of each 
sample according to the kit protocol (Millipore; Cat #: 
OB100). Free fatty acid release was measured using 50 μL 
of each sample according to the kit protocol (BioVision, 
Milpitas, CA, USA; Cat #: K612).
Antibodies
Anti-STAT5A (L-20; sc1081; rabbit polyclonal) and 
anti-ERK1/2 (C-16; sc-93; rabbit polyclonal) antibodies 
were purchased from Santa Cruz Biotechnology. We 
used both mouse monoclonal (clone 8-5-2; 05-495) 
and rabbit polyclonal (07-586) anti-phospho-STAT5 
A/B (Tyr 694/699) antibodies from Millipore to detect 
tyrosine phosphorylated STAT5 (STAT5pY). Anti-
adiponectin (PA1-054; rabbit polyclonal) antibody was 
purchased from Thermo Scientific. Anti-DBC1 (5693; 
rabbit polyclonal) and anti-SIRT1 (1F3; 8469; mouse 
monoclonal) antibodies were purchased from Cell 
Signaling Technology.
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Figure 1
DBC1 is present in the nucleus of adipocytes and can be 
co-immunoprecipitated with STAT5A. (A) Fully differentiated 3T3-L1 
adipocytes were treated with 5 nM murine growth hormone (GH) or an 
equivalent volume of vehicle (10 mM NaHCO3) for 20 min. Monolayers 
were collected and subjected to subcellular fractionation. As shown in 
the left-hand portion of the figure, cytosolic and nuclear protein extracts 
(300 µg total protein/sample) were immunoprecipitated (IP) with an 
anti-STAT5A antibody. The mock sample contained anti-STAT5A antibody 
without cell extract. The right-hand portion of the figure are direct 
Western blot (WB) controls containing 75 µg total protein that were 
directly subjected to Western blotting without IP. STAT5pY represents 
phosphorylated STAT5 at tyrosine 694/699. This is a representative figure 
of an experiment independently performed three times. (B) The 
monolayers of fully differentiated 3T3-L1 adipocytes were harvested and 
whole-cell protein extracts were prepared. The left-hand portion of the 
figure shows IP of whole-cell extract containing 400 µg of total protein, 
anti-DBC1 antibody and IP buffer. Mock sample contained anti-DBC1 
antibody without cell extract. The right-hand portion of the figure 
contains WB controls. This is a representative figure of an experiment 
independently performed three times on different groups of adipocytes.
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Statistical analysis
All data were analyzed by two-tailed unpaired Student’s 
t-test (using GraphPad Prism 7). Results from studies of 
cultured adipocytes are shown as mean ± standard error 
of the mean (s.e.m.). Results were considered statistically 
significant when P < 0.05.
Results
We previously utilized a semi-nonbiased screening 
approach to identify novel STAT5 interaction partners 
using co-immunoprecipitation and mass spectrometry. 
Pyruvate dehydrogenase complex-E2 (PDC-E2) was 
the first interacting protein that we reported from this 
screen (Richard et  al. 2017). In our present study, we 
report that DBC1 was also identified as a potential novel 
STAT5A-interacting protein in 3T3-L1 adipocytes. To 
validate our mass spectrometry results, we performed 
co-immunoprecipitation with a STAT5A antibody followed 
by Western blotting using an anti-DBC1 antibody, and 
we examined both cytosolic and nuclear extracts from 
mature 3T3-L1 adipocytes in the absence or presence of 
an acute GH treatment, a condition that activates STAT5A 
(Fig. 1A). These studies revealed that DBC1 interacts with 
STAT5A in the nucleus and that the nuclear localization of 
DBC1, unlike STAT5A, was not dependent on GH-induced 
STAT5 tyrosine phosphorylation (Fig.  1A). To further 
validate that these two proteins were present in the 
same protein complex in adipocytes, we demonstrated 
that STAT5A could also be pulled down by a reverse 
co-immunoprecipitation using a DBC1 antibody (Fig. 1B). 
Together, these experiments corroborate that DBC1 is 
present in a complex with STAT5A under physiological 
conditions in the nucleus of adipocytes and that this 
interaction is not dependent upon GH stimulation or 
STAT5 tyrosine phosphorylation.
To assess the function of the DBC1/STAT5A interaction, 
we performed siRNA experiments to knockdown DBC1 in 
mature adipocytes. The goal was to determine if DBC1 
expression had any effect on STAT5 phosphoactivation or 
transcriptional activity. In these studies, we examined the 
ability of GH to induce STAT5A activation by measuring 
STAT5A tyrosine phosphorylation. Western blot analysis 
showed that loss of DBC1 levels did not have an effect on 
levels of STAT5A or STAT5pY (Fig. 2).
To confirm that the loss of DBC1 protein affected 
its activity in adipocytes, we performed additional 
experiments to measure SIRT1 activity. It is well established 
that SIRT1 activity is negatively regulated by DBC1 (Kim 
et al. 2008, Zhao et al. 2008). As expected, our experiments 
showed an increase in SIRT1 activity when DBC1 protein 
levels were reduced (***P < 0.001), suggesting that the 
knockdown of DBC1 also affected its activity in adipocytes 
as judged by SIRT1 activity (Fig. 3A). Induction of SIRT1 
deacetylase activity in HeLa extract with the addition of 
NAD+ or trichostatin A (TricA) was used as a control to 
confirm validity of the deacetylase assay (Fig. 3B).
Tyrosine phosphorylated STAT5A can activate or 
repress the expression of many genes. To determine if 
DBC1 expression had any effect on the transcriptional 
activity of STAT5, we examined the expression of several 
STAT5 target genes following GH treatment of mature 
adipocytes for 1–4 h under control or DBC1-knockdown 
conditions. The expression of STAT5A target genes (Socs3, 
Cish and Bcl6) was assessed by qPCR. It is known that 
Socs3 and Cish gene expression are highly induced 1 h 
following STAT5 activation (Matsumoto et  al. 1997, 
Karlsson et al. 1999, Barclay et al. 2007), whereas Bcl6 gene 
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Figure 2
Knockdown of DBC1 does not affect STAT5A protein expression or STAT5 
tyrosine phosphorylation in 3T3-L1 adipocytes. Fully differentiated 3T3-L1 
adipocytes were transfected once per day for 2 days with non-targeting 
siRNA or DBC1 siRNA. After 48 h, adipocytes were serum deprived for 4 h 
and treated with 5 nM murine growth hormone (GH) or equivalent 
volume of vehicle (10 mM NaHCO3) for 20 min. Monolayers were collected 
and 75 μg of total protein was separated using SDS-PAGE. Protein 
expression was visualized using Western blotting with the antibodies 
indicated to the left of panel. ERK was used as a loading control. Three 
biological replicates were used for each treatment group in each 
individual experiment. This is a representative figure of an experiment 
independently performed three times on different groups of adipocytes.
Figure 3
Knockdown of DBC1 increases the deacetylase activity of SIRT1 in 3T3-L1 
adipocytes. (A) SIRT1 deacetylase activity was measured in samples 
prepared by immunoprecipitating SIRT1 from 3T3-L1 adipocytes 
transfected with non-targeting (NT) or DBC1 siRNA. Each IP reaction 
contained 75 μg of total protein, anti-SIRT1 antibody and IP buffer.  
(B) HeLa extract was used as a control to assess SIRT1 deacetylase activity. 
The graph shows the requirement of NAD+ for SIRT deacetylase activity 
and Trichostatin A (TricA) inhibiting the Fluor de Lys substrate 
deacetylation in HeLa nuclear extract. Statistical significance was 
determined using a Student’s t-test and assigned as ***P < 0.001. 
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expression is reduced following 4 h of GH treatment (Lin 
et al. 2014). The data showed the expected regulation of 
Socs3, Cish and Bcl6 gene expression following 1 h of GH 
treatment. However, there were no differences in mRNA 
levels of these genes in adipocytes with reduced DBC1 
expression (Fig. 4). Similar results were observed for other 
STAT5A target genes such as adiponectin, Fasn and Pdk4 
(data not shown).
Although DBC1 did not have a profound impact 
on STAT5A transcriptional activity, there is evidence 
in the literature that DBC1 may affect adipose tissue 
inflammation (Moreno-Navarrete et  al. 2015b). We 
explored this on the cellular level by investigating the 
ability of DBC1 to modulate TNFα action in adipocytes. 
TNFα is known to increase basal lipolysis, promote the 
expression and secretion of pro-inflammatory cytokines, 
such as IL-6, and reduce the secretion of anti-inflammatory 
hormones, such as adiponectin (Berghe et  al. 2000, He 
et al. 2016). To investigate the effects of DBC1 on TNFα 
action, we used siRNA to knockdown DBC1 in mature 
3T3-L1 adipocytes. Gene expression analysis showed that 
a loss of DBC1, independent of TNFα treatment, increased 
Glut4 gene expression (***P < 0.01 for Vehicle treatment 
and **P < 0.01 for TNFα treatment) but did not have a 
profound effect on TNFα-mediated changes in expression 
of Mcp1 or adiponectin (Fig. 5A). Western blot analysis was 
used to assess the level of DBC1 protein knockdown and 
the effectiveness of TNFα treatment, as judged by reduced 
adiponectin protein levels (Fig. 5B), which was consistent 
with the changes observed in adiponectin gene expression 
(Fig. 5A). We also assessed whether DBC1 expression had 
an impact on TNFα-mediated lipolysis. Both free fatty 
acid and glycerol release were measured from mature 
adipocytes following TNFα treatment in control and 
DBC1-knockdown adipocytes. We observed a modest, but 
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statistically significant, decrease in TNFα-induced glycerol 
(***P < 0.005) and free fatty acid (*P < 0.05) release with 
reduced DBC1 expression (Fig. 6).
Discussion
STAT5A is a transcription factor that can mediate the 
effects of GH (Zvonic et al. 2003) and promote adipocyte 
development (Floyd & Stephens 2003, Stewart et al. 2011). 
In adipocytes, STAT5A regulates genes that contribute 
to insulin sensitivity and the endocrine properties of 
adipocytes (Hogan & Stephens 2005, White et  al. 2007, 
2016). To further understand the mechanisms involved 
in the contribution of STAT5A to fat cell function, we 
sought to identify novel STAT5A-interacting proteins 
in adipocytes using a co-immunoprecipitation/mass 
spectrometry approach. We recently published data 
describing this approach and the identification of 
components of the pyruvate dehydrogenase complex as 
STAT5A-binding proteins (Richard et  al. 2017). Another 
STAT5A-binding protein that we identified with this 
approach was the nuclear protein, DBC1. DBC1 has been 
shown to mediate cellular responses to stress and regulate 
the activity of a variety of enzymes and transcription 
factors in different cell types (Joshi et al. 2013). Our novel 
observations demonstrate that DBC1 can be present in 
the same protein complex as STAT5A in the nucleus of 
3T3-L1 adipocytes (Fig. 1). This interaction was observed 
with endogenous proteins and could be detected by 
immunoprecipitating either STAT5A or DBC1. In addition 
to this observation, our results reveal that this interaction 
is not dependent on STAT5A tyrosine phosphorylation 
(Fig. 1A).
To assess the potential function of the STAT5A/DBC1 
association, we examined STAT5A expression levels as 
well as STAT5A tyrosine phosphorylation in adipocytes 
that had substantially decreased levels of DBC1. These 
studies revealed that loss of DBC1 did not alter STAT5A 
total protein levels or its ability to be activated, as judged 
by tyrosine phosphorylation (Fig.  2). We also examined 
the ability of STAT5A to regulate gene expression in 
adipocytes with reduced DBC1 expression. To our surprise, 
there were no profound changes in the expression of 
several STAT5A target genes in DBC1-deficient adipocytes, 
which strongly indicates that DBC1 levels do not affect 
the transcriptional activity of STAT5A (Fig.  4). Although 
there were some modest differences in Socs3 and Cish 
gene expression following 4-h GH treatment in DBC1 
knockdown adipocytes, these results were not statistically 
significant. The effectiveness of siRNA-mediated DBC1 
knockdown was assessed by examining gene and protein 
expression levels of DBC1 (Figs 2, 4 and 5) as well as SIRT1 
deacetylase activity (Fig.  3) since DBC1 is a well-known 
negative regulator of SIRT1 (Kim et  al. 2008, Zhao et  al. 
2008, Liu et al. 2016). As expected, we observed an increase 
in SIRT1 activity, indicating that the activity of DBC1 was 
likely altered in the DBC1-knockdown adipocytes (Fig. 3). 
Presumably, we only observed a modest increase in SIRT1 
Figure 4
Knockdown of DBC1 in mature adipocytes does 
not affect the ability of GH to alter the expression 
of STAT5A target genes. Fully differentiated 
3T3-L1 adipocytes were transfected once per day 
for two days with non-targeting (NT) siRNA or 
DBC1 siRNA. After 48 h, adipocytes were serum 
deprived for 4 h and treated with 5 nM murine 
growth hormone (GH) or equivalent volume of 
vehicle (V; 10 mM NaHCO3) for 1, 2, or 4 h. Total 
RNA was isolated and subjected to quantitative 
RT-PCR analysis. Each graph represents a different 
gene. The examined genes were normalized to 
Nono. This is a representative figure of an 
experiment independently performed three times 
on different groups of adipocytes.
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activity because DBC1 is only one of many regulators of 
SIRT1 activity in mature adipocytes. Other studies have 
shown that a variety of other factors including the cAMP/
PKA pathway and AROS (active regulator of SIRT1) can 
positively regulate SIRT1 (Kim et al. 2007, Chao & Tontonoz 
2012). Collectively, our observations suggest that DBC1 
levels do not affect the transcriptional activity of STAT5A.
Since there was evidence suggesting that DBC1 may 
have a pro-inflammatory role in adipocytes by increasing 
the expression of NF-κB-regulated inflammatory cytokines 
(Moreno-Navarrete et al. 2015b), we examined the actions 
of TNFα on adipocytes with reduced levels of DBC1. 
TNFα can induce insulin resistance, in part, through 
the transcriptional repression of the Glut4 gene in 
adipocytes (Stephens & Pekala 1991, Stephens et al. 1997, 
Ruan et  al. 2002a) and by activating NF-κB (Ruan et  al. 
2002b). In addition, TNFα can repress adiponectin gene 
expression in mouse and human adipocytes (Fasshauer 
et al. 2002, Degawa-Yamauchi et al. 2005). Both increased 
GLUT4 protein expression in adipocytes (Carvalho et al. 
2005, Atkinson et  al. 2013) and increased adiponectin 
levels (Fu et al. 2005) are associated with improvements 
in insulin sensitivity. Knockdown of DBC1 did not 
alter TNFα-mediated induction of pro-inflammatory 
MCP-1 or repression of anti-inflammatory adiponectin 
(Fig.  5A). However, we consistently observed that a 
loss of DBC1 protein resulted in increased Glut4 gene 
expression, which suggests a potential role for DBC1 in 
glucose regulation. Studies in HepG2 cells have shown a 
knockdown of DBC1 results in the upregulation of PEPCK 
(phosphoenolpyruvate carboxykinase) and consequently 
effects glucose production (Nin et al. 2014). Experiments 
performed with inguinal fat tissue from DBC1-null 
mice also showed increased PEPCK expression in DBC1-
deficient tissue (Moreno-Navarrete et al. 2015b). Although 
additional experiments will be required to determine if 
there are any direct effects of DBC1 on glucose metabolism 
or Glut4 gene expression, our results suggest that DBC1 
is a likely a negative regulator of GLUT4 in adipocytes 
(Fig. 5A).
Although the loss of DBC1 did not profoundly affect 
TNFα regulation of several genes in adipocytes (Fig.  5), 
we did observe that alteration of DBC1 levels affected 
TNFα-induced lipolysis. Our studies revealed a modest 
Figure 5
Knockdown of DBC1 in mature adipocytes results 
in increased Glut4 gene expression but does not 
alter TNFα-mediated changes in gene expression. 
Fully differentiated 3T3-L1 adipocytes were 
transfected once per day for two days with 
non-targeting (NT) siRNA or DBC1 siRNA. After 
54 h, media was replaced with 1% calf and cells 
were treated with 0.75 nM TNFα overnight or 
equivalent volume of vehicle (0.1% BSA/PBS). 
After 16 h, cells were re-treated again with vehicle 
or TNFα for 2 h. Finally, monolayers were 
harvested for RNA and protein. (A) Total RNA was 
isolated and subjected to quantitative RT-PCR 
analysis. The examined genes (each represented 
by separate graph) were normalized to Nono. 
Statistical significance was determined using a 
Student’s t-test and assigned as **P < 0.01, 
***P < 0.001, and ****P < 0.0001. (B) 75 μg of total 
protein was separated using SDS-PAGE. Protein 
expression was visualized using Western blotting 
and the antibodies indicated on the left of panel. 
Three biological replicates were used for each 
treatment group in each individual experiment. 
This is a representative figure of an experiment 
independently performed three times on 
different groups of adipocytes.
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but significant reduction in glycerol and free fatty acid 
release in DBC1-knockdown adipocytes under TNFα-
stimulated conditions (Fig.  6). This effect could be 
considered metabolically favorable, which is also evident 
by the increased Glut4 expression we observed with loss 
of DBC1. Overall, our observations are consistent with 
the phenotype of the DBC1-knockout mice fed a high-fat 
diet that are more insulin sensitive and have decreased 
circulating FFA (Escande et  al. 2015). Our data showing 
that loss of DBC1 increases Glut4 expression and reduces 
TNFα-induced lipolysis suggests that the loss of DBC1 in 
adipocytes may contribute to the metabolically protected 
phenotype of the DBC1-null mice. Although additional 
experiments in adipocyte-specific DBC1 knockout mice 
will be needed, the current data are consistent with a role 
of DBC1 in promoting metabolic dysfunction. Decreased 
FFA levels are typically associated with a metabolically 
healthy phenotype. Whereas an increase in glycerol 
and fatty acids is often harmful and associated with the 
clinical manifestations of metabolic syndrome, which also 
include obesity and insulin resistance (Boden 1999, Arner 
& Rydén 2015). Our results show a decrease in glycerol 
and free fatty acid release from TNFα-stimulated DBC1-
deficient adipocytes that occurs in a cell autonomous 
manner and suggest that DBC1 plays a direct or indirect 
role in the ability of TNFα to induce lipolysis.
Although these novel observations revealed that DBC1 
is present in a protein complex with STAT5A in adipocyte 
nuclei (Fig. 1), most of our functional studies reproducibly 
generated negative observations. The loss of DBC1 did 
not affect STAT5A expression (Fig.  2), STAT5A tyrosine 
phosphorylation (Fig. 2) or the expression of STAT5A target 
genes (Fig. 4). Although DBC1 is clearly in a complex with 
STAT5, and loss of DBC1 did result in expected increase in 
SIRT1 activity (Fig. 3), we were unable to perturb STAT5A 
expression, activation or activity. We did, however, have 
two consistent effects that accompanied loss of DBC1 
expression in adipocytes: (1) increased Glut4 expression 
and (2) a statistically significant decrease in TNFα-induced 
lipolysis. Nevertheless, it is unlikely that these functions 
of DBC1 are related to its interaction with STAT5A. Further 
studies are needed to identify additional proteins present 
in the DBC1/STAT5A complex, to elucidate the function 
of the DBC1/STAT5A interaction and to investigate the 
mechanism of DBC1’s ability to modulate TNFα-induced 
lipolysis.
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